Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People between 18 and 75 years old
• People whose general health and ability to carry out daily activities meets a certain standard (referred to as an ECOG performance score of less than 2 — confirm with trial site what this means for a specific situation)
• People who have a type of lymphoma confirmed by tissue testing that is classified as "CD30 positive"
• People who have already received at least one previous cancer treatment
• People with a life expectancy of at least 3 months
• People who have at least one measurable area of lymphoma larger than 1 cm, as assessed by standard lymphoma imaging criteria
• People whose previous cancer treatment was completed more than 4 weeks before enrolling, and whose side effects from that treatment have largely resolved
• People who have had an autologous stem cell transplant (a procedure using the patient's own stem cells) are eligible, provided it took place more than 3 months before enrolling
• People whose bone marrow, liver, kidneys, and heart are functioning at adequate levels

Who may not be able to join:

• People whose lymphoma is classified as "CD30 negative"
• People whose body processes a certain group of medications very rapidly due to their genetic makeup (known as CYP2D6 ultra-rapid metabolisers — confirm with trial site)
• People who are currently taking certain medications that affect how the body breaks down drugs (specifically CYP2D6 inhibitors or strong or moderate CYP3A inhibitors — confirm with trial site)
• People who have had a severe allergic reaction to a type of cancer treatment that targets CD30
• People with a known allergy or intolerance to any component of the study drug
• People with active cancer spread to the brain or active central nervous system involvement — though people who had brain involvement treated with radiotherapy at least 3 months before enrolling, have no current neurological symptoms, and are no longer taking steroids may still be considered, and would require a brain MRI scan
• People with serious uncontrolled health conditions, including active infections, certain heart conditions, or significant mental health or social circumstances that could affect safe participation in the trial
• People with a known positive test for HIV or AIDS
• People who have had another cancer diagnosis within the past 3 years, with certain exceptions for some early-stage or non-invasive cancers (such as certain cervical, skin, or bladder conditions — confirm with trial site)
• People who have had major surgery or a significant physical trauma within the 28 days before enrolling, or who have not yet recovered from the effects of such surgery or trauma
• People who have received a vaccine within 30 days before enrolling
• People with active bleeding in the digestive tract, or who have had such bleeding within the past month
• People who are pregnant or breastfeeding; women who could become pregnant must have a negative pregnancy test within 7 days before enrolling
• People who are currently participating in another clinical trial, or who withdrew from one within the past 4 weeks
• People who are unable to swallow and keep down oral medication, or who have significant conditions affecting the digestive system that would interfere with absorbing the study drug (such as removal of the stomach or part of the small bowel, ulcerative colitis, symptomatic inflammatory bowel disease, or bowel obstruction)
• People whom the trial investigators determine are unsuitable for other reasons

Important: Always verify eligibility with the trial site directly before applying.